Korro Bio, Inc. (KRRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Korro Bio, Inc. (KRRO) has a cash flow conversion efficiency ratio of -0.134x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.07 Million) by net assets ($119.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Korro Bio, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read KRRO total liabilities for a breakdown of total debt and financial obligations.
Korro Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korro Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yatsen Holding
NYSE:YSG
|
-0.032x |
|
A Paradise Acquisition Corp.
NYSE:APAD
|
-0.001x |
|
Oriola-KD Oyj B
HE:OKDBV
|
0.229x |
|
LAUNCH TECH CO. H YC-01
F:LAN
|
N/A |
|
AMA Group Ltd
AU:AMA
|
0.125x |
|
STLLR Gold Inc.
TO:STLR
|
-0.045x |
|
Jalles Machado S/A
SA:JALL3
|
0.104x |
|
MIRC Electronics Limited
NSE:MIRCELECTR
|
-0.387x |
Annual Cash Flow Conversion Efficiency for Korro Bio, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Korro Bio, Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see KRRO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.44 Million | $-78.56 Million | -1.527x | -307.82% |
| 2024-12-31 | $160.41 Million | $-60.07 Million | -0.374x | +5.43% |
| 2023-12-31 | $169.91 Million | $-67.28 Million | -0.396x | -173.10% |
| 2022-12-31 | $-99.03 Million | $-53.65 Million | 0.542x | +320.81% |
| 2021-12-31 | $130.82 Million | $-32.09 Million | -0.245x | -4.50% |
| 2020-12-31 | $192.49 Million | $-45.19 Million | -0.235x | -214.83% |
| 2019-12-31 | $167.36 Million | $34.22 Million | 0.204x | -46.55% |
| 2018-12-31 | $-44.51 Million | $-17.02 Million | 0.382x | -22.42% |
| 2017-12-31 | $-29.64 Million | $-14.61 Million | 0.493x | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more